Overcoming cultural barriers to being agile in distributed teams

Context: Agile methods in offshored projects have become increasingly popular. Yet, many companies have found that the use of agile methods in coordination with companies located outside the regions of early agile adopters remains challenging. India has received particular attention as the leading destination of offshoring contracts due to significant cultural differences between sides of such contracts. Alarming differences are primarily rooted in the hierarchical business culture of Indian organizations and related command-and-control management behavior styles. Objective: In this study, we attempt to understand whether cultural barriers persist in distributed projects in which Indian engineers work with a more empowering Swedish management, and if so, how to overcome them. The present work is an invited extension of a conference paper. Method: We performed a multiple-case study in a mature agile company located in Sweden and a more hierarchical Indian vendor. We collected data from five group interviews with a total of 34 participants and five workshops with 96 participants in five distributed DevOps teams, including 36 Indian members, whose preferred behavior in different situations we surveyed. Results: We identified twelve cultural barriers, six of which were classified as impediments to agile software development practices, and report on the manifestation of these barriers in five DevOps teams. Finally, we put forward recommendations to overcome the identified barriers and emphasize the importance of cultural training, especially when onboarding new team members. Conclusions: Our findings confirm previously reported behaviors rooted in cultural differences that impede the adoption of agile approaches in offshore collaborations, and identify new barriers not previously reported. In contrast to the existing opinion that cultural characteristics are rigid and unchanging, we found that some barriers present at the beginning of the studied collaboration disappeared over time. Many offshore members reported behaving similarly to their onshore colleagues.acceptedVersio

Further Investigation of the Survivability of Code Technical Debt Items

Context: Technical Debt (TD) discusses the negative impact of sub-optimal decisions to cope with the need-for-speed in software development. Code Technical Debt Items (TDI) are atomic elements of TD that can be observed in code artefacts. Empirical results on open-source systems demonstrated how code-smells, which are just one type of TDIs, are introduced and "survive" during release cycles. However, little is known about whether the results on the survivability of code-smells hold for other types of code TDIs (i.e., bugs and vulnerabilities) and in industrial settings. Goal: Understanding the survivability of code TDIs by conducting an empirical study analysing two industrial cases and 31 open-source systems from Apache Foundation. Method: We analysed 133,670 code TDIs (35,703 from the industrial systems) detected by SonarQube (in 193,196 commits) to assess their survivability using survivability models. Results: In general, code TDIs tend to remain and linger for long periods in open-source systems, whereas they are removed faster in industrial systems. Code TDIs that survive over a certain threshold tend to remain much longer, which confirms previous results. Our results also suggest that bugs tend to be removed faster, while code smells and vulnerabilities tend to survive longer.Comment: Submitted to the Journal of Software: Evolution and Process (JSME

A Monitoring Infrastructure for the Quality Assessment of Cloud Services

Service Level Agreements (SLAs) specify the strict terms under which cloud services must be provided. The assessment of the quality of services being provided is critical for both clients and service providers. In this context, stakeholders must be capable of monitoring services delivered as Software as a Service (SaaS) at runtime and of reporting any eventual non-compliance with SLAs in a comprehensive and flexible manner. In this paper, we present the definition of an SLA compliance monitoring infrastructure, which is based on the use of [email protected], its main components and artifacts, and the interactions among them. We place emphasis on the configuration of the artifacts that will enable the monitoring, and we present a prototype that can be used to perform this monitoring. The feasibility of our proposal is illustrated by means of a case study, which shows the use of the components and artifacts in the infrastructure and the configuration of a specific plan with which to monitor the services deployed on the Microsoft Azure© platform

The Impact of Ownership and Contribution Alignment on Code Technical Debt Accumulation

Software development organisations strive to maintain their effectiveness while the complexity of the systems they develop continues to grow. To tackle this challenge, organisations tend to be organised into small teams working with components that can be developed separately. Here, organisations must design their architecture and organisational structures in a way that enables communication and minimises dependencies, and helps teams reduce code and architectural degradation. Ensuring that each small independent team is responsible for components they primarily contribute is one approach to achieving this goal. This study aims at understanding the impact of ownership and contribution alignment on accumulation of code technical debt and how abrupt changes in team constellation affect teams' effectiveness in managing TD. We conducted an embedded case study in a company developing a very large software system, analysing ten components belonging to 1 team. During the studied period, the team was split into two, and the components owned by them were distributed between the two new teams. With high degrees of contribution alignment, we noticed a negative correlation between contribution alignment and TD Density before the team split. In 4 components, this correlation is statistically significant. This means a higher contribution alignment degree implies a lower TD Density. After the split, we observe a negative correlation in 3 components. The positive correlation observed in the other 5 components could be attributed to low contribution alignment, leading to difficulties in managing TD. Our findings suggest that contribution alignment can be important in controlling TD in software development organisations. Making teams responsible for the quality of components they have more expertise over and minimising dependencies between teams can help organisations mitigate the growth of TD.Comment: Submitted to Transactions on Software Engineering (TSE

Cinética de imbibición e isotermas de adsorción de humedad de la semilla de jamaica (Hibiscus sabdariffa L.)

La jamaica es un arbusto que se cultiva para comercializar el cáliz de sus flores, pero como subproducto se obtienen las semillas, que por su valor nutritivo y alto rendimiento representan un potencial económico considerable. El objetivo de este trabajo fue describir la cinética de imbibición y las isotermas de adsorción de humedad a 25, 35 y 45ºC en tres variedades cultivadas en México ("Criolla", "China" y "Sudán"). Los resultados mostraron que el proceso de imbibición describe una curva que se ajusta al modelo de Weibull, con coeficientes α de 12.99, 8.81 y 2.21 horas y β de 0.83, 1.70 y 0.72 para las variedades Criolla, China y Sudán, respectivamente. Los modelos de GAB, y de Chung-Pfost describieron adecuadamente las isotermas de adsorción. La humedad de la capa monomolecular (coeficiente a del modelo de GAB) resultó entre 3.97 y 5.71% b.s., lo cual representa una actividad de agua entre 0.1 y 0.30. Los calores isostéricos totales de adsorción obtenidos en el intervalo de humedades de equilibrio de 6 a 22% b.s., oscilaron entre 52.85 y 42.90 .90 kJmּol-1, 60.99 y 43.41 kJmּol-1 y 51.23 y 43.20 kJmּol-1para las variedades Criolla, China y Sudán, respectivamente. A humedades de equilibrio iguales o superiores a 12 % b.s., el calor isostérico fue similar a la entalpía de vaporización del agua, pero a humedades inferiores a 6% b.s., éste alcanzó los valores más elevados

Assets in Software Engineering: What are they after all?

During the development and maintenance of software-intensive products or services, we depend on various assets. These assets are important to the feasibility of the project and influence product's final quality. However, despite their central role in the software development process, little thought is yet invested into what assets eventually are, often resulting in many terms and underlying concepts being mixed and used inconsistently. A precise terminology of assets and related concepts, such as asset degradation, are crucial for setting up a new generation of cost-effective software engineering practices. In this position paper, we critically reflect upon the resulting notion of assets in software engineering. As a starting point, we define the terminology and concepts of assets and extend the reasoning behind them. We explore assets' characteristics such as value and persistence. We discuss what asset degradation is, its various types and the implications that asset degradation might bring for the planning, realisation, and evolution of software-intensive products and services over time. With our work, we aspire to contribute to a more standardised definition of assets in software engineering and foster research endeavours and their practical dissemination in a common, more unified direction.Comment: Manuscript submitted to the Journal of Systems and Softwar

The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

Background: Patients with type 2 diabetes mellitus (T2DM) present subclinical left ventricular systolic and/or diastolic dysfunction (LVD). Dipeptidyl peptidase-4 (DPP4) inactivates peptides that possess cardioprotective actions. Our aim was to analyze whether the activity of circulating DPP4 is associated with echocardiographically defined LVD in asymptomatic patients with T2DM. Methods: In this cross-sectional study, we examined 83 T2DM patients with no coronary or valve heart disease and 59 age and gender-matched non-diabetic subjects. Plasma DPP4 activity (DPP4a) was measured by enzymatic assay and serum amino-terminal pro-brain natriuretic peptide (NT-proBNP) was measured by enzyme-linked immunosorbent assay. LV function was assessed by two-dimensional echocardiographic imaging, targeted M-mode recordings and Doppler ultrasound measurements. Differences in means were assessed by t-tests and one-way ANOVA. Associations were assessed by adjusted multiple linear regression and logistic regression analyses. Results: DPP4a was increased in T2DM patients as compared with non-diabetic subjects (5855 ± 1632 vs 5208 ± 957 pmol/min/mL, p < 0.05). Clinical characteristics and echocardiographic parameters assessing LV morphology were similar across DPP4a tertiles in T2DM patients. However, prevalence of LVD progressively increased across incremental DPP4a tertiles (13%, 39% and 71%, all p < 0.001). Multivariate regression analysis confirmed the independent associations of DPP4a with LVD in T2DM patients (p < 0.05). Similarly, multiple logistic regression analysis showed that an increase of 100 pmol/min/min plasma DPP4a was independently associated with an increased frequency of LVD with an adjusted odds ratio of 1.10 (95% CI, 1.04 to 1.15, p = 0.001). Conclusions: An excessive activity of circulating DPP4 is independently associated with subclinical LVD in T2DM patients. Albeit descriptive, these findings suggest that DPP4 may be involved in the mechanisms of LVD in T2DM

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.17.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days >= 30%,>= 50%,>= 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice